Arrowhead Pharmaceuticals Inc   (ARWR)
Other Ticker:  
Price: $28.9800 $0.06 0.207%
Day's High: $29.48 Week Perf: 0.07 %
Day's Low: $ 28.80 30 Day Perf: 24.81 %
Volume (M): 875 52 Wk High: $ 42.48
Volume (M$): $ 25,349 52 Wk Avg: $31.37
Open: $29.48 52 Wk Low: $22.87

 Market Capitalization (Millions $) 3,098
 Shares Outstanding (Millions) 107
 Employees 211
 Revenues (TTM) (Millions $) 241
 Net Income (TTM) (Millions $) -209
 Cash Flow (TTM) (Millions $) 3
 Capital Exp. (TTM) (Millions $) 177

Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals Inc is a biopharmaceutical company based in Pasadena, California, that is focused on the development of RNA interference (RNAi) therapeutics. The company is dedicated to developing innovative therapies that target diseases with high unmet medical needs, including rare and chronic diseases such as liver diseases, cardiovascular diseases, oncology, and more.

Arrowhead's RNAi technology is based on a gene-silencing technology that uses small RNA molecules that interfere with the expression of specific genes, leading to the inhibition of the disease process. The company's leading RNAi technology platform, called TRiM (Targeted RNAi Molecule), is designed to deliver RNAi therapeutics to specific tissues and organs with high specificity, efficacy, and safety. Arrowhead's TRiM platform is specifically designed to overcome the challenges of effective delivery of RNAi drugs, including stability, targeting, and biodistribution.

The company's lead clinical development program is aimed at the treatment of liver diseases such as alpha-1 antitrypsin deficiency (AATD), hypercholesterolemia, and others. The company has also initiated clinical testing of RNAi therapeutics for cardiovascular diseases, including hypertension and pulmonary arterial hypertension (PAH), and oncology, including liver cancer (hepatocellular carcinoma) and solid tumors.

Arrowhead has collaborations with various pharmaceutical companies and academic institutions, including Takeda Pharmaceutical Company, Amgen, and The University of Texas MD Anderson Cancer Center, among others. The company's management team consists of experienced scientists, entrepreneurs, and executives, including President and CEO Christopher Anzalone, Ph.D.; Chief Medical Officer Javier San Martin, M.D.; and Chief Scientific Officer Kevin Fitzgerald, Ph.D.

Arrowhead Pharmaceuticals Inc is publicly traded on the NASDAQ market under the ticker symbol ARWR. The company has a market capitalization of over $5 billion as of August 2021, reflecting strong investor confidence in its innovative RNAi technology platform and pipeline of promising drug candidates.

   Company Address: 177 E. Colorado Blvd Pasadena 91105 CA
   Company Phone Number: 304-3400   Stock Exchange / Ticker: NASDAQ ARWR
   ARWR is expected to report next financial results on February 05, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Evofem Biosciences Inc

Serious revenue fall, at Evofem Biosciences Inc in the fiscal third quarter of 2023

For the third quarter of 2023 Evofem Biosciences Inc had turn a round to earnings by posting EPS of $0.10 per share compare to $-0.04 a year prior and net profit per share turned positive from $-5.43 per share from the preceding financial reporting period. The revenue declined widely by -19.761 % to $5.11 million from $6.37 million in the corresponding financial reporting period a year prior and sequentially Revenue doubled by 107.974 % from $2.46 million.

Shuttle Pharmaceuticals Holdings Inc

Shuttle Pharmaceuticals Holdings Inc. Faces a Bumpy Ride: Operating Results Decline in Recent Fiscal Period for Major Pharmaceutical Preparations Company

In the dynamic and ever-evolving world of the stock market, there are always exciting new opportunities waiting to be discovered. While the major players in the pharmaceutical industry tend to grab most of the headlines, it is often the lesser-known companies that can offer hidden gems for astute investors. One such company, Shuttle Pharmaceuticals Holdings Inc (SHPH), has recently published its financial report for the third quarter of 2023, shedding light on its performance and potential for growth.
Despite reporting an operating loss of $-1.599146 million for the third quarter of 2023, SHPH has displayed a promising upward trajectory. Although the company has not released its top-line figures yet, it is essential to consider its previous accomplishments to put its recent performance into context. In the third quarter of 2022, SHPH recorded an operating loss of $-0.821468 million, indicating significant progress within just one year.

Cingulate Inc

The company declared operating shortfall in the third quarter of 2023

Bearish Sentiment Surrounding Cingulate Inc: A Closer Look at the Financials
Cingulate Inc, a Kansas City-based biopharmaceutical company operating in the Major Pharmaceutical Preparations sector, recently reported an operating shortfall of $-5.749674 million for the third quarter of 2023. This is a significant decrease when compared to the operating shortfall of $-3.968362 million reported in the same quarter of the previous year.
This decline in financial performance is a cause for concern. While companies in the pharmaceutical industry often experience fluctuations in revenue and profitability due to the challenges of developing innovative drugs, Cingulate Inc's consistent downward trend in operating shortfall is worrisome.
The management of Cingulate Inc aims to develop lucrative revenue sources by utilizing their proprietary Precision Timed Release (PTR) drug delivery platform technology. However, the results for the third quarter of 2023 indicate that these efforts have not yet yielded positive outcomes. The operating shortfall soared to $-5.979 million, indicating that the company's attempts to generate revenue have not been successful.

Harrow Inc

Harrow Inc Achieves Remarkable 49.84% Top-line Surge during Exceptional Q3 2023 Earnings Season

As the Chief Financial Correspondent at The , I would like to delve into the financial results of Harrow Inc for the fiscal period ending September 30, 2023. These results tell a story of progress and resilience in a volatile market. Despite recent decline in share values, Harrow Inc's steady financial improvement and increased revenue demonstrate its ability to navigate challenging times.
Profitability and Earnings:
Harrow Inc has made substantial progress in terms of earnings per share (EPS). In the fiscal year ending September 30, 2023, the company reduced its loss per share from $-0.24 to $-0.13. This represents a significant improvement in profitability, reflecting the company's strong management and strategic decisions.

Renovorx Inc

Renovorx Inc Witnesses Decline in Q3 2023 Financial Performance, Sets Path for Recovery

As the earnings season progresses, financial results of various companies are being unveiled. One notable player in the Major Pharmaceutical Preparations sector, Renovorx Inc, recently disclosed its operating loss for the most recent fiscal period ending September 30, 2023. While the figures may seem concerning at first glance, a closer look reveals some interesting developments that could shape the company's future trajectory.
Operating Loss Reduction:
Renovorx Inc reported an operating loss of $-2.983 million for the third quarter of 2023. However, comparing this figure with the same period in 2022, we see a positive trend. In the third quarter of 2022, the operating loss was $-2.161 million, indicating a reduction in losses year-over-year. This demonstrates the company's efforts to streamline operations and improve efficiency, which is essential for its long-term viability.


Arrowhead Pharmaceuticals Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com